Larvol Delta - Outlook-Therapeutics-Announces-FDA-Acceptance-of-Resubmitted-Biologics-License-Application-for-ONS5010LYTENAVA-bevacizumabvikg-as-a-Treatment-for-Wet-AMD

Lytenava (bevacizumab-vikg) - Outlook Therap

https://www.globenewswire.com/news-release/2026/06/16/3312535/0/en/outlook-therapeutics-announces-fda-acceptance-of-resubmitted-biologics-license-application-for-ons-5010-lytenava-bevacizumab-vikg-as-a-treatment-for-wet-amd.html

Jun 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next